Fig. 3From: Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort studyThe virological responses in patients receiving 12-week or 24-week SOF + DCV ± RBV therapyBack to article page